HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Exogenous NAD(+) supplementation protects H9c2 cardiac myoblasts against hypoxia/reoxygenation injury via Sirt1-p53 pathway.

Abstract
Nicotinamide adenine dinucleotide (NAD(+) ) not only transfers electrons in mitochondrial respiration, but also acts as an indispensable cosubstrate for Sirt1, the class III histone/nonhistone deacetylase. However, NAD(+) is depleted in myocardial ischemia/reperfusion (IR) injury. The objective of this study was to investigate the role of exogenous NAD(+) supplementation in hypoxia/reoxygenation (HR)-stressed H9c2 cardiac myoblasts. Firstly, the effects of distinct treating time points and doses of NAD(+) supplementation on the viability of HR-stressed H9c2 cells were detected. Secondly, intracellular NAD(+) levels in HR-stressed H9c2 cells at various extracellular NAD(+) concentrations were determined. Thirdly, the role of NAD(+) supplementation in HR-induced cell apoptosis and its relevance to Sirtuin 1-p53 pathway were investigated. Exogenous NAD(+) supplementation elevated intracellular NAD(+) level and reduced HR-induced cell death in both time- and concentration-dependent manners. It appeared that NAD(+) supplementation exerted the greatest protection when extracellular concentration ranged from 500 to 1000 μm and when NAD(+) was added immediately after reoxygenation began. NAD(+) replenishment restored Sirt1 activity, reduced the acetylation level of p53 (Lys373 & 382), and attenuated cell apoptosis in HR-stressed H9c2 cells, whereas inhibition of Sirt1 activity alleviated the effects of NAD(+) replenishment. These results indicated that exogenous NAD(+) supplementation attenuated HR-induced cell apoptosis, which was at least partly mediated by restoring Sirt1 activity and subsequently inhibiting p53 activity via deacetylating p53 at lysine 373 and 382.
AuthorsLing Liu, Ping Wang, Xinwei Liu, Dongwei He, Canxin Liang, Ying Yu
JournalFundamental & clinical pharmacology (Fundam Clin Pharmacol) Vol. 28 Issue 2 Pg. 180-9 (Apr 2014) ISSN: 1472-8206 [Electronic] England
PMID23384296 (Publication Type: Journal Article)
Copyright© 2012 The Authors Fundamental and Clinical Pharmacology © 2012 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd.
Chemical References
  • Tumor Suppressor Protein p53
  • NAD
  • Sirt1 protein, rat
  • Sirtuin 1
  • Oxygen
Topics
  • Animals
  • Apoptosis (drug effects)
  • Cell Culture Techniques
  • Cell Hypoxia (drug effects)
  • Cell Line
  • Cell Survival (drug effects)
  • Dose-Response Relationship, Drug
  • Myoblasts, Cardiac (drug effects, metabolism, pathology)
  • Myocardial Reperfusion Injury (metabolism)
  • NAD (metabolism, pharmacology)
  • Oxygen (metabolism)
  • Rats
  • Signal Transduction (drug effects)
  • Sirtuin 1 (metabolism)
  • Time Factors
  • Tumor Suppressor Protein p53 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: